Pharmacokinetic-pharmacodynamic modeling of terbutaline bronchodilation in asthma. 1986

B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel

The study of terbutaline pharmacodynamics in patients with asthma is hampered by interfering stimuli when steady-state methods are employed. With pharmacokinetic-dynamic modeling, many of these interferences can be avoided. Using this technique, we studied the effect of terbutaline on lung function in 10 asthmatic patients with greater than 15% lung function reversibility. Terbutaline plasma concentrations, forced expiratory volume in 1 second (FEV1) airway resistance (Raw), and specific airway conductance (sGaw) were measured before and during 7 hours after subcutaneous dosing with 0.75 mg terbutaline. A hyperbolic concentration-effect relation was found. Fitting the time course of the effects required an effect compartment in the integrated model. Thus the delay between plasma concentration and effect time course was characterized by the rate constant ke0. Essentially the same ke0 was found for FEv1, Raw, and sGaw, indicating that the concerning receptors are "localized" in the same pharmacokinetic compartment. Of the lung function measures, sGaw was less sensitive to terbutaline than Raw and FEV1, whereas the latter tended to be the most sensitive one.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008448 Maximal Expiratory Flow Rate The airflow rate measured during the first liter expired after the first 200 ml have been exhausted during a FORCED VITAL CAPACITY determination. Common abbreviations are MEFR, FEF 200-1200, and FEF 0.2-1.2. Forced Expiratory Flow 0.2-1.2,Forced Expiratory Flow 200-1200,Flow Rate, Maximal Expiratory,MEFR,Forced Expiratory Flow 0.2 1.2,Forced Expiratory Flow 200 1200
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D013726 Terbutaline A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. Arubendol,Asthmoprotect,Brethaire,Brethine,Bricanyl,Bricanyl SA,Butaliret,Butalitab,Contimit,KWD-2019,Monovent,Taziken,Tedipulmo,Terbasmin,Terbul,Terbutalin AL,Terbutalin Stada,Terbutalin-ratiopharm,Terbutaline Sulfate,Terbuturmant,terbutalin von ct,KWD 2019,KWD2019,Terbutalin ratiopharm

Related Publications

B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
January 2000, Archives of medical research,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
January 2012, Critical reviews in biomedical engineering,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
January 1996, Methods and findings in experimental and clinical pharmacology,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
May 2005, Journal of pain and symptom management,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
June 1981, Journal of pharmacokinetics and biopharmaceutics,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
August 2016, Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
January 1981, Critical reviews in bioengineering,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
January 2000, Annual review of pharmacology and toxicology,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
July 2013, Pharmacological reviews,
B Oosterhuis, and M C Braat, and C M Roos, and J Wemer, and C J Van Boxtel
February 1997, Journal of pharmaceutical sciences,
Copied contents to your clipboard!